Adaptive Biotechnologies logo

ADPT - Adaptive Biotechnologies Share Price

$28.21 0.8  3.1%

Last Trade - 17/01/20

Sector
Healthcare
Size
Large Cap
Market Cap £2.60bn
Enterprise Value £2.18bn
Revenue £59.7m
Position in Universe 1483rd / 6416
Bullish
Bearish
Unlock ADPT Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ADPT Revenue Unlock ADPT Revenue

Net Income

ADPT Net Income Unlock ADPT Revenue

Normalised EPS

ADPT Normalised EPS Unlock ADPT Revenue

PE Ratio Range

ADPT PE Ratio Range Unlock ADPT Revenue

Dividend Yield Range

ADPT Dividend Yield Range Unlock ADPT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ADPT EPS Forecasts Unlock ADPT Revenue
Profile Summary

Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. It also focuses on developing immune-mediated therapies in oncology and other disease areas.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated September 8, 2009
Public Since June 27, 2019
No. of Shareholders: n/a
No. of Employees: 346
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 124,316,080
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ADPT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ADPT
Upcoming Events for ADPT
Tuesday 14th January, 2020
Adaptive Biotechnologies Corp at JPMorgan Healthcare Conference
Similar to ADPT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.